ArticleEuropean journal of epidemiology2016
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Article in European journal of epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Pooled it
- Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2017Pooled it
- The journey of the cardiovascular polypill from its conception to the WHO List of Essential Medicines.Nature cardiovascular research · 2025Review
- Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study.Health science reports · 2024Article
- Comparing screening based on the NHS Health Check and Polypill Prevention Programmes in the primary prevention of heart attacks and strokes.Journal of medical screening · 2024Article
- A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries.Global heart · 2024Article
- Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.Therapeutic advances in cardiovascular disease · 2018Review
- [Management of different cardiovascular risk factors with a combination tablet (polypill)].Herz · 2018Review
- The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention.Iranian journal of pharmaceutical research : IJPR · 2018Article
- The Rotterdam Study: 2018 update on objectives, design and main results.European journal of epidemiology · 2017Article
- Starting the polypill: the use of a single age cut-off in males and females.Journal of medical screening · 2017Article
- Could patents interfere with the development of a cardiovascular polypill?Journal of translational medicine · 2016Article
- Cardiovascular diseases in mega-countries: the challenges of the nutrition, physical activity and epidemiologic transitions, and the double burden of disease.Current opinion in lipidology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary prevention of cardiovascular disease is a public health priority. To assess the costs and benefits of a Polypill Prevention Programme using a daily 4-component polypill from age 50 in the UK, we determined the life years gained without a first myocardial infarction (MI) or stroke, together with the total service cost (or saving) and the net cost (or saving) per year of life gained without a first MI or stroke. This was estimated on the basis of a 50 % uptake and a previously published 83 % treatment adherence. The total years of life gained without a first MI or stroke in a mature programme is 990,000 each year in the UK. If the cost of the Polypill Prevention Programme were £1 per person per day, the total cost would be £4.76 bn and, given the savings (at 2014 prices) of £2.65 bn arising from the disease prevented, there would be a net cost of £2.11 bn representing a net cost per year of life gained without a first MI or stroke of £2120. The results are robust to sensitivity analyses. A national Polypill Prevention Programme would have a substantial effect in preventing MIs and strokes and be cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.